MIB Agents OsteoBites and osTEAo

Listen in on honest conversations as Osteosarcoma Warriors and survivors discusses all aspects of the young adult cancer experience in this brave and frank podcast. 

--  

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Dr. Yustein is a pediatric oncologist and physician-scientist with significant training in molecular and cellular biology. During his time as the Director of the Faris D. Ewing Sarcoma Center at Texas Children's Hospital, he recognized the need for improving our understanding of the molecular pathogenesis of sarcomas and the identification of new therapeutic avenues, especially for patients with therapeutic resistant and/or metastatic disease. His laboratory has tremendous interest and experience in merging innovative murine models and patient-derived resources towards garnering molecular insights into sarcoma initiation, development/resistance and metastatic progression and translating these findings towards testing novel therapeutic interventions for these aggressive malignancies. His laboratory has developed and characterized robust metastatic genetically engineered mouse models (GEMM) for pediatric sarcomas, including osteosarcoma (OS), which recapitulate the human disease initiation and progression. Subsequently, his lab has derived primary sarcoma lines from the GEMM tumors that can be orthotopically transplanted into wild type C57BL/6 mice and monitored using in vivo imaging for further characterization of sarcoma development and progression. He recently moved to Atlanta to join Emory University as a Professor in the Department of Pediatrics, Hematology-Oncology Division and the Director of Solid Tumor Translational Research Children’s Healthcare of Atlanta and the Aflac Cancer and Blood Disorders Center.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

--

John A. Ligon, MD, is an assistant professor in the department of pediatrics at the University of Florida College of Medicine. Dr. Ligon earned his medical degree from the Baylor College of Medicine in Houston. After he completed his residency in pediatrics at the University of Texas Southwestern Medical Center in Dallas, he pursued a fellowship in pediatric hematology and oncology at Johns Hopkins University and the National Cancer Institute in Maryland. In the following years, he completed a senior fellowship in pediatric immunotherapy at the National Cancer Institute and another in pediatric sarcoma at Johns Hopkins University.

Dr. Ligon is board-certified in both general pediatrics and pediatric hematology and oncology by the American Board of Pediatrics. In addition to his numerous original research publications and editorial review appointments, he is a member of various professional societies, such as the Children’s Oncology Group and the American Association for Cancer Research. Dr. Ligon has been honored with a variety of awards for his research skills and academic excellence. His research interests include immunotherapy, tumors and bloodstream infections.

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

A pediatric oncologist and physician-scientist, Dr. Crompton is the Research Co-Director of the Solid Tumor Center at Dana-Farber/Boston Children’s Cancer and Blood Disorder Center and he is an Assistant Professor of Pediatrics at Harvard Medical School.  His research focuses on utilizing genomic and proteomic technologies to identify and validate new therapeutic targets for pediatric solid tumors and to develop non-invasive biomarkers of treatment response and resistance in these diseases. His lab has developed new approaches to estimating circulating tumor DNA levels from liquid biopsy samples from patients with pediatric solid tumors. He joins us on OsteoBItes to discuss a Children’s Oncology Group registry initiative called Project:Everychild.

--

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

Dr. Chris Collier is a dedicated surgeon-scientist who leads innovative basic science and clinical research to improve outcomes for his patients. He is an Assistant Professor of Orthopaedic Surgery at the Indiana University School of Medicine. He has authored numerous publications, textbook chapters, earned multiple research awards and grants, and presented his research nationally and internationally.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

Join us for OsteoBites with Dr. Alanna Church from Boston Children's Hospital. She will discuss the study recently published in Nature Medicine with Dr. Katie Janeway and many other collaborators, demonstrating the clinical utility of molecular tumor profiling for children with cancer. This cohort includes 345 children and AYA cancer patients from 12 institutions who had molecular tumor profiling using targeted NGS panels, including 64 patients with osteosarcoma. Molecular alterations with potential impact on the diagnosis, prognosis or treatment were identified in 86% of patients.​ She hopes these results will help to advocate for molecular profiling for all children with cancer. Read the paper here: https://rdcu.be/cQgmj

Reminder that this July for Sarcoma Awareness month, join us for our Virtual OutRunning OsteoSarcoma event! When you run/walk/cycle with us, you can help Cause A Cure. With MIB, no one walks through Osteosarcoma alone - let’s go OutRunning together! Register at: https://mibagents.swoogo.com/OutRunning

Also to commemorate Sarcoma Awareness Month, MIB is partnering with Kendra Scott for a Multi-City give back event taking place the weekend July 15-17! By making a purchase during this weekend, you are helping raise funds and awareness for Osteosarcoma.

This September, we encourage you to Be Bold and Go Gold for Childhood Cancer Awareness Month! Make & Sell Bows in your community OR Make a donation this summer and get a bow that shows you care. Contact [email protected] to volunteer today!

Learn more about the clinical trial process, tips for finding all possible trials, and considerations when choosing a trial.

Brenna Carswell, a childhood cancer survivor and mother of two, holds a Master's degree in Counseling Psychology. Although oncology has been a key part of her life for over 30 years, she has worked directly with patients, families, researchers, and clinicians for the last 8 years. Along with pediatric cancer research and trials, Brenna is passionate about humanitarian causes and child welfare. She makes time for fun and escapes to the beach with her daughters as often as possible.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

Dr. Janeway received her medical degree from Harvard Medical School in 2000. She subsequently completed her residency in Pediatrics at Children's Hospital, Boston. She was a Chief Resident at Children's Hospital, Boston, and then completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute / Children's Hospital, Boston. In 2007, Dr. Janeway joined the staff of Dana-Farber and Children's Hospital, Boston, where she is a pediatric hematologist-oncologist and investigator with a research focus of pediatric sarcomas.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

Dr. John Healey, Chief, Orthopaedic Service; Stephen McDermott Chair in Surgery, is an orthopaedic surgeon who specializes in caring for people with sarcomas and noncancerous tumors of the bones and soft tissue. He has particular expertise in removing tumors while preserving limbs, as well as a special interest in treating children who have bone cancers, such as osteosarcoma and Ewing sarcoma. Dr. Healey has been with Memorial Sloan Kettering since 1984 and performs approximately 260 surgeries each year. In addition to his role as Chief of the Orthopaedic Service at MSK, he is a professor of orthopaedic surgery at Weill Cornell Medical College. Nationally, he has served as chair of the Children’s Oncology Group Orthopaedics Section, president of the International Society of Limb Salvage, and president of the Association of Bone and Joint Surgeons, as well as on the boards of several musculoskeletal and orthopaedic organizations. Dr. Healey is also an advisor to the National Comprehensive Cancer Network.

Brandon was diagnosed with Osteosarcoma in the left proximal Tibia in January 2019, between his first and second semesters of senior year at the University of Maryland. He completed the standard 9 month chemotherapy roadmap and received limb salvage surgery in April 2019, completing treatment in October 2019. He graduated with his class in May 2019 and ultimately moved to Manhattan where he now works for Citibank. He has been cancer free (knock on wood) for 2.5 years.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨